Gold Investment Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.59M Buy
56,466
+1,074
+2% +$28.6K 0.49% 66
2025
Q4
$1.38M Buy
55,392
+1,394
+3% +$35.2K 0.44% 69
2025
Q3
$1.38M Buy
53,998
+1,117
+2% +$27.6K 0.46% 69
2025
Q2
$1.31M Buy
52,881
+80
+0.2% +$1.87K 0.49% 66
2025
Q1
$1.34M Buy
52,801
+2,488
+5% +$65.1K 0.57% 65
2024
Q4
$1.33M Buy
50,313
+265
+0.5% +$7.19K 0.56% 63
2024
Q3
$1.45M Sell
50,048
-3,668
-7% -$107K 0.61% 61
2024
Q2
$1.5M Buy
53,716
+120
+0.2% +$3.3K 0.64% 59
2024
Q1
$1.49M Buy
53,596
+7,526
+16% +$209K 0.6% 61
2023
Q4
$1.33M Buy
+46,070
New +$1.39M 0.57% 63

Other funds holding PFE

Gold Investment Management's PFE Position: Q1 2026 in Review

Gold Investment Management increased its Pfizer (PFE) stake by 1.9% in Q1 2026, buying an estimated $28.6K and bringing the position to 56,466 shares worth $1.59M. The position accounts for 0.49% of the portfolio, ranked #66.

Gold Investment Management first reported a position in PFE in Q4 2023 and has held it in 10 quarters since. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Gold Investment Management held 56,466 shares of Pfizer worth $1.59M as of Q1 2026.
  • Gold Investment Management bought 1,074 Pfizer shares in Q1 2026, an estimated $28.6K.
  • Pfizer made up 0.49% of Gold Investment Management's portfolio in Q1 2026, its #66 holding.
  • Gold Investment Management first reported a position in Pfizer in Q4 2023 and has held it in 10 quarters since.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Gold Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.